DoubleLine ETF Adviser’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
Other funds holding BMY
DoubleLine ETF Adviser's BMY Position: Q2 2026 in Review
DoubleLine ETF Adviser reduced its Bristol-Myers Squibb (BMY) stake by 10% in Q2 2026, selling an estimated $155K and leaving 23,354 shares worth $1.35M. The position accounts for 0.56% of the portfolio, ranked #63.
DoubleLine ETF Adviser first reported a position in BMY in Q1 2026 and has held it in 2 quarters since. The position peaked at $1.58M in Q1 2026. 2,517 funds tracked by Wall St. Rank hold BMY as of Q2 2026.
- DoubleLine ETF Adviser held 23,354 shares of Bristol-Myers Squibb worth $1.35M as of Q2 2026.
- DoubleLine ETF Adviser sold 2,700 Bristol-Myers Squibb shares in Q2 2026, an estimated $155K.
- Bristol-Myers Squibb made up 0.56% of DoubleLine ETF Adviser's portfolio in Q2 2026, its #63 holding.
- DoubleLine ETF Adviser first reported a position in Bristol-Myers Squibb in Q1 2026 and has held it in 2 quarters since.
- DoubleLine ETF Adviser's Bristol-Myers Squibb position peaked at $1.58M in Q1 2026.
- 2,517 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.
Based on DoubleLine ETF Adviser's 13F filing for Q2 2026, filed 14 Aug 2026.